anti-cancer drug safe and effective for treating light chain (AL) amyloidosis

(Boston University School of Medicine) There's a new treatment option available for patients with AL amyloidosis: daratumumab. Studied in a prospective clinical trial, only one of the two clinical trials of this agent in AL amyloidosis worldwide, researchers have found this anti-cancer drug to be well tolerated and effective in patients with relapsed AL amyloidosis when used with appropriate pre- and post-infusion medications.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news